Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Palliative Pharmacotherapy: State-of-the-Art Management of Symptoms in Patients With Cancer.

Cancer control : journal of the Moffitt Cancer Center·2015
Same author

Pharmacological Management of Cancer-Related Pain.

Cancer control : journal of the Moffitt Cancer Center·2015
Same author

Palliative Oncologists: Specialists in the Science and Art of Patient Care.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2015
Same author

Fentanyl (transmucosal).

Journal of pain and symptom management·2012
Same author

Ketamine for pain: an update of uses in palliative care.

Journal of palliative medicine·2012
Same author

Octreotide.

Journal of pain and symptom management·2011
Same journal

Relationships Between Advance Care Planning Engagement, Patients' Religious Practices, and Spirituality.

The American journal of hospice & palliative care·2026
Same journal

The Efficacy of Spiritual Care Intervention on Readmissions of Hospitalized Patients Receiving Palliative Care: A Quasi-Experimental Pilot Study Proposal.

The American journal of hospice & palliative care·2026
Same journal

Nurse-Led Advance Care Planning Interventions for Patients with Advanced Cancer: A Systematic Review.

The American journal of hospice & palliative care·2026
Same journal

Self-Reported Cannabis Use and Symptom Burden Among Patients With Cancer Receiving Palliative Care.

The American journal of hospice & palliative care·2026
Same journal

Efficacy of Oxygen Therapy for the Relief of Dyspnea in Palliative Care: A Systematic Review.

The American journal of hospice & palliative care·2026
Same journal

Survival Heterogeneity in U.S. Hospice Patients: A Retrospective Cohort Study.

The American journal of hospice & palliative care·2026
See all related articles

Related Experiment Video

Updated: Jun 19, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Palliative oncology: thalidomide.

Eric E Prommer1

  • 1Division of Hematology and Oncology, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA. prommer.eric@mayo.edu

The American Journal of Hospice & Palliative Care
|October 22, 2009
PubMed
Summary
This summary is machine-generated.

Thalidomide, once avoided for birth defects, is now a key treatment for multiple myeloma. It works by boosting immunity and inhibiting cytokines, offering new hope in cancer therapy.

Related Experiment Videos

Last Updated: Jun 19, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Area of Science:

  • Oncology
  • Hematology
  • Palliative Care

Background:

  • Thalidomide, previously withdrawn due to teratogenicity, has been repurposed as a vital therapeutic agent.
  • Its resurgence is driven by its efficacy in treating multiple myeloma.

Purpose of the Study:

  • To review the current applications of thalidomide in oncology, hematology, and palliative care.
  • To elucidate the mechanism of action, efficacy, and safety profile of thalidomide.

Main Methods:

  • Review of existing literature on thalidomide's use in multiple myeloma and palliative care.
  • Analysis of its pharmacological properties, including metabolism and mechanism of action.

Main Results:

  • Thalidomide demonstrates efficacy as a first-line treatment for multiple myeloma, particularly in combination regimens.
  • Its mechanism involves immune system activation, antiangiogenic effects, and cytokine inhibition.
  • Potential adverse effects include peripheral neuropathy, constipation, and deep vein thrombosis.

Conclusions:

  • Thalidomide is an effective treatment option for multiple myeloma, despite potential side effects.
  • Its role extends to palliative care for conditions like anorexia-cachexia syndrome.
  • Continued research and careful patient monitoring are essential for optimizing thalidomide therapy.